EUVIMEDEUVIMED entdecken
Crossref

RAD51 inhibition ameliorates secondary hyperparathyroidism: bioinformatic prediction and experimental verification

Xuemei Sun, Qingqing Luo, Shen Yan, Fuli Yang, Jiajun Zhou, Fanze Yang, Yijing Cheng, Wandong Yang, Yongfeng Li

American Journal of Translational Research · 2026 · 18 (10) · 9251-9269

DOI: 10.62347/jnce1282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Xuemei Sun und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Sun, X., Luo, Q., Yan, S., Yang, F., Zhou, J., Yang, F., Cheng, Y., Yang, W., & Li, Y. (2026). RAD51 inhibition ameliorates secondary hyperparathyroidism: bioinformatic prediction and experimental verification. American Journal of Translational Research, 18(10), 9251-9269. https://doi.org/10.62347/jnce1282

Vancouver

Sun X, Luo Q, Yan S, Yang F, Zhou J, Yang F, et al. RAD51 inhibition ameliorates secondary hyperparathyroidism: bioinformatic prediction and experimental verification. American Journal of Translational Research. 2026;18(10):9251-9269. doi:10.62347/jnce1282

BibTeX
@article{Sun2026,
  author = {Sun, Xuemei and Luo, Qingqing and Yan, Shen and Yang, Fuli and Zhou, Jiajun and Yang, Fanze and Cheng, Yijing and Yang, Wandong and Li, Yongfeng},
  title = {RAD51 inhibition ameliorates secondary hyperparathyroidism: bioinformatic prediction and experimental verification},
  journal = {American Journal of Translational Research},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {9251--9269},
  doi = {10.62347/jnce1282}
}
Kostenlos starten →